Providing an overview on antipsychotics: Schizophrenia a psychiatric challenge? A 2017 Update: Schizophrenia a psychiatric challenge? A 2017 Update

Natalie Schellack; Moliehi Matlala

Providing an overview on antipsychotics: Schizophrenia a psychiatric challenge? A 2017 Update: Schizophrenia a psychiatric challenge? A 2017 Update

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

Abstract

© 2017 Medpharm. Psychosis is an umbrella term used in the description of various conditions involving delusions and hallucinations. This article focuses mainly on the management of schizophrenia. Schizophrenia is a complex disorder, which provides many pharmacotherapy-related challenges. Advances have been made in the treatment of the condition; however, this requires a team approach, with the pharmacist having to monitor treatment both for safety and efficacy. The involvement of medicines that might modulate the N-methyl-D-aspartate (NMDA) receptors is an exciting development that should be monitored.

Original language	English
Pages (from-to)	16-23
Number of pages	8
Journal	SA Pharmaceutical Journal
Volume	84
Issue number	3
Publication status	Published - 1 Jan 2017

Keywords

Antipsychotics
First-generation antipsychotics
Schizophrenia
Second-generation antipsychotics

Cite this

@article{2deef4e56c054b0bba64a88254273810,

title = "Providing an overview on antipsychotics: Schizophrenia a psychiatric challenge? A 2017 Update: Schizophrenia a psychiatric challenge? A 2017 Update",

abstract = "{\textcopyright} 2017 Medpharm. Psychosis is an umbrella term used in the description of various conditions involving delusions and hallucinations. This article focuses mainly on the management of schizophrenia. Schizophrenia is a complex disorder, which provides many pharmacotherapy-related challenges. Advances have been made in the treatment of the condition; however, this requires a team approach, with the pharmacist having to monitor treatment both for safety and efficacy. The involvement of medicines that might modulate the N-methyl-D-aspartate (NMDA) receptors is an exciting development that should be monitored.",

keywords = "Antipsychotics, First-generation antipsychotics, Schizophrenia, Second-generation antipsychotics",

author = "Natalie Schellack and Moliehi Matlala",

year = "2017",

month = jan,

day = "1",

language = "English",

volume = "84",

pages = "16--23",

journal = "SA Pharmaceutical Journal",

issn = "1015-1362",

publisher = "Medpharm Publications",

number = "3",

}

TY - JOUR

T1 - Providing an overview on antipsychotics: Schizophrenia a psychiatric challenge? A 2017 Update

T2 - Schizophrenia a psychiatric challenge? A 2017 Update

AU - Schellack, Natalie

AU - Matlala, Moliehi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2017 Medpharm. Psychosis is an umbrella term used in the description of various conditions involving delusions and hallucinations. This article focuses mainly on the management of schizophrenia. Schizophrenia is a complex disorder, which provides many pharmacotherapy-related challenges. Advances have been made in the treatment of the condition; however, this requires a team approach, with the pharmacist having to monitor treatment both for safety and efficacy. The involvement of medicines that might modulate the N-methyl-D-aspartate (NMDA) receptors is an exciting development that should be monitored.

AB - © 2017 Medpharm. Psychosis is an umbrella term used in the description of various conditions involving delusions and hallucinations. This article focuses mainly on the management of schizophrenia. Schizophrenia is a complex disorder, which provides many pharmacotherapy-related challenges. Advances have been made in the treatment of the condition; however, this requires a team approach, with the pharmacist having to monitor treatment both for safety and efficacy. The involvement of medicines that might modulate the N-methyl-D-aspartate (NMDA) receptors is an exciting development that should be monitored.

KW - Antipsychotics

KW - First-generation antipsychotics

KW - Schizophrenia

KW - Second-generation antipsychotics

UR - http://www.scopus.com/inward/record.url?scp=85021261044&partnerID=8YFLogxK

M3 - Literature review

SN - 1015-1362

VL - 84

SP - 16

EP - 23

JO - SA Pharmaceutical Journal

JF - SA Pharmaceutical Journal

IS - 3

ER -

Providing an overview on antipsychotics: Schizophrenia a psychiatric challenge? A 2017 Update: Schizophrenia a psychiatric challenge? A 2017 Update

Abstract

Keywords

Other files and links

Fingerprint

Cite this